Journal of Proteomics & Bioinformatics
Open Access
ISSN: 0974-276X
ISSN: 0974-276X
Philippe Soubeyran
Cancer Research Center of Marseille, France
Posters & Accepted Abstracts: J Proteomics Bioinform
Pancreatic cancer remains nowadays one of the deadliest forms of cancer. This situation is partly due to the fact that these tumors become rapidly resistant to any kind of therapies. Our aim is to identify new resistance mechanisms which would explain the multi-resistant phenotype of pancreatic cancer cells. Chemotherapies trigger cellular stress responses that help the cell to survive. These responses are based on the post-translational modification (PTMs) of key components of these pathways. Among all possible PTMs, modifications mediated by ubiquitin family members appear to play major roles in these processes but, so far, have not been really studied in this context. Therefore, we intent to identify alterations of the ubiquitin and ubiquitin-like pathways and to determine which ones are involved in resistance mechanisms. To this end, we use cell lines expressing tagged version of each ubiquitin and ubiquitin-like studied, to specifically purify modified proteins and identify them by tandem mass spectrometry. Hence, we have established the PTMs profiles of pancreatic cancer cells, treated and not treated with chemotherapeutic drugs, resistant or not to them. We could observe that chemotherapeutic treatment, as well as acquisition of the resistant phenotype, is associated with an important modulation of PTMs profiles. Among those, we could validate the role of the modification of one candidate regarding the survival of the cell challenge by gemcitabine. Hence, studying alterations of PTMs mediated by the ubiquitin family of proteins associated with cancer resistance has the potential to reveal important new molecular mechanisms involved in the phenomenon.
Email: philippe.soubeyran@inserm.fr